KINGSTON, Jamaica — MSN Laboratories, a global pharmaceutical leader headquartered in India, has officially launched a subsidiary in Jamaica, marking a major step forward in its mission to enhance healthcare access across the Caribbean.

The new Jamaican entity will serve as a hub for delivering essential medicines to the region, initially targeting chronic and acute therapy areas such as cardiovascular diseases, diabetes, oncology, infectious diseases, and central nervous system (CNS) disorders.

“We are delighted to establish a direct presence in Jamaica,” said Dr Manne Satyanarayana Reddy, founder, chairman & managing director of MSN Group. “This move aligns with our mission to deliver high-quality and affordable healthcare solutions to people in every corner of the world.”

With more than two decades of pharmaceutical expertise, MSN Laboratories aims to bring to Jamaica its legacy of innovation, advanced manufacturing and global regulatory experience.

Indian High Commissioner to Jamaica, Shri Mayank Joshi, who was present at the launch said, “This type of opening is not only going to bring momentum for affordable and quality medicine to Jamaica from MSN but also improving and contributing a much larger framework to the healthcare sector of Jamaica,” he said.

Meanwhile, Senior Vice President for Emerging Markets B, Dr Jayapala Reddy noted that the relationship between Jamaica and India continues to strengthen.

“We feel that Jamaica is an important market for us going forward. We have got a good number of approvals. We have a very good market share. Some of our products are household and I would say that thousands of patients have been using them for a long time and the portfolio that we have is going to offer a lot of benefits to doctors, pharmacies and patients. Jamaica is a very important market for us” he explained.

The Jamaican subsidiary is the latest addition to MSN’s expanding global footprint, which spans over 100 countries. The company’s portfolio includes more than 500 active pharmaceutical ingredients (APIs) and 400 finished formulations across 35 major therapeutic areas.

Founded in 2003 and headquartered in Hyderabad, India, MSN Group operates 25 state-of-the-art manufacturing facilities and an integrated research and development centre that supports both API and formulation development. The company holds over 1,000 national and international patents and is a recognised leader in regulatory filings, including being the world’s top filer of active US Drug Master Files (DMFs).